Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;108(2):275-93.
doi: 10.1111/j.1360-0443.2012.04054.x. Epub 2012 Oct 17.

Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Natalya C Maisel  1 , Janet C Blodgett, Paula L Wilbourne, Keith Humphreys, John W Finney
Affiliations
Review

Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Natalya C Maisel et al. Addiction. 2013 Feb.

Abstract

Aims: Although debates over the efficacy of oral naltrexone and acamprosate in treating alcohol use disorders tend to focus on their global efficacy relative to placebo or their efficacy relative to each other, the underlying reality may be more nuanced. This meta-analysis examined when naltrexone and acamprosate are most helpful by testing: (i) the relative efficacy of each medication given its presumed mechanism of action (reducing heavy drinking versus fostering abstinence) and (ii) whether different ways of implementing each medication (required abstinence before treatment, detoxification before treatment, goal of treatment, length of treatment, dosage) moderate its effects.

Methods: A systematic literature search identified 64 randomized, placebo-controlled, English-language clinical trials completed between 1970 and 2009 focused on acamprosate or naltrexone.

Results: Acamprosate had a significantly larger effect size than naltrexone on the maintenance of abstinence, and naltrexone had a larger effect size than acamprosate on the reduction of heavy drinking and craving. For naltrexone, requiring abstinence before the trial was associated with larger effect sizes for abstinence maintenance and reduced heavy drinking compared with placebo. For acamprosate, detoxification before medication administration was associated with better abstinence outcomes compared with placebo.

Conclusions: In treatment for alcohol use disorders, acamprosate has been found to be slightly more efficacious in promoting abstinence and naltrexone slightly more efficacious in reducing heavy drinking and craving. Detoxification before treatment or a longer period of required abstinence before treatment is associated with larger medication effects for acamprosate and naltrexone respectively.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Medication type (naltrexone versus acamprosate) as a moderator of abstinence outcomes aggregate (abstinence rate, percent days abstinent, and time to first drink). Top half of forest plot presents the effect sizes for naltrexone studies, and the bottom half presents the effect sizes for acamprosate studies.
Figure 2
Figure 2
Medication type (naltrexone versus acamprosate) as a moderator of heavy drinking outcomes aggregate (heavy drinking rate, percent days heavy drinking, time to first heavy drink, drinking quantity). Top half of forest plot presents the effect sizes for naltrexone studies, and the bottom half presents the effect sizes for acamprosate studies.
See this image and copyright information in PMC

Comment in

References

Appendix A. Full list of studies included in the meta-analysis

    1. Ahmadi J, Babaeebeigi M, Maany I, Porter J, Mohagheghzadeh M, Ahmadi N, et al. Naltrexone for alcohol-dependent patients. Ir J Med Sci. 2004;173(1):34–37. - PubMed
    1. Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, et al. Naltrexone combined with either cognitive behavioral or motivational enhancementy therapy for alcohol dependence. J Clin Psychopharmacol. 2005;25(4):349–357. - PubMed
    1. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry. 1999;156(11):1758–1764. - PubMed
    1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–2017. - PubMed
    1. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, et al. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003;27(7):1142–1149. - PubMed

References

    1. Department of Veterans Affairs and Department of Defense . VA/DoD Clinical Practice Guideline for Management of Substance Use Disorders (SUD) Washington, DC: 2009.
    1. American Psychiatric Association . Physician Consortium for Performance Improvement, National Committee for Quality Assurance. Substance use disorders performance measurement set. American Medical Association; National Committee for Quality Assurance; 2008.
    1. National Institute for Health and Clinical Excellence. Alcohol Use Disorders: Diagnosis, assessment and management of harmful drinking and alcohol dependence. 2011
    1. Substance Abuse and Mental Health Services Administration . The N-SSATS report: services provided by substance abuse treatment facilities in the United States. Office of Applied Studies; Rockville (MD): Sep, 2009. - PubMed
    1. Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36:584–9. - PMC - PubMed

MeSH terms